Days after getting a recommendation for approval in Europe, AstraZeneca PLC has been given the green light in the US to market Fasenra (benralizumab) as a treatment for severe asthma and an alternative to GlaxoSmithKline PLC’s Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab).
Specifically, the US Food and Drug Administration has approved Fasenra for the add-on maintenance treatment of patients with severe asthma...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
